14-3-3zeta, Potential Lung Cancer Gene Target
Filed in archive Drugs, Vaccines and Therapeutics , Gene Therapy , Genomics, Proteomics and Bioinformatics on December 27, 2007
Researchers have identified a gene target called 14-3-3zeta for selective anti-cancer drugs. Using RNAi techniques, they discovered that when 14-3-3zeta is turned off, lung cancer cells become less able to form new tumor colonies under laboratory conditions.
While the authors found that the cells with 14-3-3zeta turned off do not grow more slowly, the cells are vulnerable to anoikis (Greek for homelessness), a form of cell death that happens when non-cancerous cells that are accustomed to growing in layers find themselves alone.
Further experiments showed that 14-3-3zeta regulates a set of proteins called the Bcl2 family that control programmed cell death, and its absence upsets the balance within the family.
The authors of the study, which has been published in the Proceedings of the National Academy of Sciences, also notes that 14-3-3zeta is also activated in other forms of cancer such as breast and oral cancers.
Source

Further experiments showed that 14-3-3zeta regulates a set of proteins called the Bcl2 family that control programmed cell death, and its absence upsets the balance within the family.
Tags: gene+therapy lung+cancer cancer gene 2007 gene+target
Vote for 14-3-3zeta, Potential Lung Cancer Gene Target:
|
Rating: 10.00 out of 4 vote(s) cast.
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
